Senate Work On Biosecurity Issues Continues Even As House Is Current Focus Of Legislative Activity

The center of political attention in the debate on decoupling US biopharma companies from China shifted away from the Senate after the Homeland Security and Government Affairs Committee advanced the BIOSECURE Act in March. But another committee appears to have continued activities on the topic, and has brought the Food and Drug Administration more directly into the issue.

FDA Principal Deputy Commissioner Namandjé Bumpus was called before members of the Senate Select Committee on Intelligence last month, alongside multiple officials from the US intelligence community, in what appeared...